Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(100.0%)

1Total

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05347992Completed

ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)

Role: lead

NCT03133286Completed

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

Role: lead

NCT03316404Completed

Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response

Role: lead

NCT05080231Completed

COVID-19 Immunity Assessment

Role: lead

NCT04859257Completed

Exploring the Biological Basis of Chronic Fatigue Syndrome

Role: lead

NCT03123133Completed

Gene Expression That Predicts Radiation Exposure in Humans

Role: lead

NCT04266860Not ApplicableCompleted

Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients

Role: collaborator

NCT03142425Unknown

Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy

Role: lead

NCT03142412Unknown

Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization

Role: lead

All 9 trials loaded